D-Minus Hemolytic Uremic Syndrome
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About D-Minus Hemolytic Uremic Syndrome

What is the definition of D-Minus Hemolytic Uremic Syndrome?
D-minus (diarrhea negative) hemolytic uremic syndrome is an extremely rare, progressive genetic disease characterized by low levels of red blood cells (hemolytic anemia), low platelets (thrombocytopenia), and an inability of the kidneys to process waste products from the blood (uremia).
What are the symptoms of D-Minus Hemolytic Uremic Syndrome?
Symptoms of D-minus hemolytic uremic syndrome may include malaise, fatigue, irritability, lethargy, decreased urine, paleness, scattered bruising, gastrointestinal bleeding, high blood pressure, headaches, double vision, facial paralysis, stroke, seizures, coma, fluid in the lungs, enlarged heart, and kidney failure.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for D-Minus Hemolytic Uremic Syndrome?
Treatment for D-minus hemolytic uremic syndrome may include intravenous nutrition and fluid replacement, kidney or peritoneal dialysis, blood transfusion, vasodilators, medications, such as eculizumab and ultomiris (favulizumab-cwyz), plasma exchange (plasmapheresis), immunosuppressive therapy, or kidney transplant.
Who are the top D-Minus Hemolytic Uremic Syndrome Local Doctors?
Robert A. Brodsky
Elite in D-Minus Hemolytic Uremic Syndrome
Pathology | Hematology | Oncology
Elite in D-Minus Hemolytic Uremic Syndrome
Pathology | Hematology | Oncology

Sidney Kimmel Comprehensive Cancer Center

401 North Broadway Street, Weinberg BLDG, Weinberg BLDG, 
Baltimore, MD 
Languages Spoken:
English

Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023. Dr. Brodsky is rated as an Elite provider by MediFind in the treatment of D-Minus Hemolytic Uremic Syndrome. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy.

Thomas D. Weyburn
Advanced in D-Minus Hemolytic Uremic Syndrome
Hematology | Oncology
Advanced in D-Minus Hemolytic Uremic Syndrome
Hematology | Oncology

Advocate Infusion Center

525 E Congress Pkwy, Ste 300, 
Crystal Lake, IL 
Languages Spoken:
English
Offers Telehealth

Thomas Weyburn is a Hematologist and an Oncologist in Crystal Lake, Illinois. Dr. Weyburn is rated as an Advanced provider by MediFind in the treatment of D-Minus Hemolytic Uremic Syndrome. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Familial Colorectal Cancer.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in D-Minus Hemolytic Uremic Syndrome
Elite in D-Minus Hemolytic Uremic Syndrome
Via Della Commenda 9, 
Milan, IT 

Gianluigi Ardissino practices in Milan, Italy. Mr. Ardissino is rated as an Elite expert by MediFind in the treatment of D-Minus Hemolytic Uremic Syndrome. His top areas of expertise are Hemolytic-Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, Atypical Hemolytic Uremic Syndrome (aHUS), and Kidney Transplant.

What are the latest D-Minus Hemolytic Uremic Syndrome Clinical Trials?
Observational Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Summary: The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Multicenter, Open-label, Single-arm, Post-Marketing Clinical Study to Evaluate the Efficacy and Safety of Ravulizumab in Participants Clinically Diagnosed as Atypical Hemolytic Uremic Syndrome

Summary: The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic syndrome (aHUS).

What are the Latest Advances for D-Minus Hemolytic Uremic Syndrome?